# DUO-E / GOG-3041 / ENGOT-EN10

Source: https://onco.cc/trials/duo-e/  
OnCo record `duo-e` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A third immunotherapy confirmed the benefit in dMMR disease and hinted that adding olaparib helps the mismatch-repair-proficient majority.

## Summary

Durvalumab alone: PFS HR 0.71 overall and 0.42 in dMMR. Durvalumab + olaparib: PFS HR 0.55 overall and 0.57 in pMMR (JCO 2023). FDA approved durvalumab with chemotherapy for dMMR disease in June 2024; the EU approved both the durvalumab and durvalumab + olaparib regimens (pMMR for the latter) in 2024.

## Fields

- Kind: Trial
- Status: positive
- Last checked: 2026-09-07
- Registry id: NCT04269200
- Phase: 3
- Setting: Newly diagnosed advanced or recurrent endometrial cancer: chemotherapy + durvalumab, then durvalumab ± olaparib maintenance, vs chemotherapy
- Sponsor: AstraZeneca
- Enrolled: 718
- Result: PFS HR 0.42 (dMMR, durvalumab); 0.57 (pMMR, durvalumab + olaparib).
- Outcomes: Progression-free survival (dMMR, durvalumab): Durvalumab + chemo vs Chemo, HR 0.42; Progression-free survival (pMMR, durvalumab + olaparib): Durvalumab + olaparib + chemo vs Chemo, HR 0.57

## Sources

- ClinicalTrials.gov NCT04269200: https://clinicaltrials.gov/study/NCT04269200
- JCO 2023: https://ascopubs.org/doi/10.1200/JCO.23.02132

## Connected records

- cancers: [Advanced or recurrent endometrial cancer](https://onco.cc/cancers/advanced-recurrent-endometrial-cancer/), [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Mismatch-repair-deficient endometrial cancer](https://onco.cc/cancers/endometrial-mmr-deficient/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- targets: [PARP](https://onco.cc/targets/parp/), [PD-L1](https://onco.cc/targets/pdl1/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Durvalumab](https://onco.cc/drugs/durvalumab/), [Olaparib](https://onco.cc/drugs/olaparib/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)
- terms: [Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR)](https://onco.cc/terms/msi/)
- pairings: [Chemotherapy + PD-1/PD-L1 blockade, first-line advanced endometrial cancer](https://onco.cc/pairings/chemo-io-first-line-endometrial/)
- key papers: [DUO-E: durvalumab with carboplatin-paclitaxel and maintenance durvalumab with or without olaparib in advanced endometrial cancer](https://onco.cc/key-papers/paper-duo-e-jco-2023/)

---
JSON: https://onco.cc/api/v1/entities/duo-e.json